Hospira pharmaceutical acquisition


Hospira, Inc., and Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, today announced

that the Hart-Scott-Rodino (HSR) review period for Hospira’s proposed acquisition of Orchid’s generic injectable pharmaceuticals business has expired with no action by the Federal Trade Commission (FTC).

The expiration of the HSR review period satisfies one of the conditions necessary for the transaction to close. Hospira and Orchid expect that, subject to the remaining customary closing conditions, the transaction will be completed in March.

Click here for the full press release.


Comments are closed.